Hims & Hers COO to Transition into Advisory Role

SAN FRANCISCO – Hims & Hers Health, Inc. (NYSE:HIMS), a company specializing in telehealth and wellness products, announced today that Chief Operating Officer Melissa Baird will be transitioning into an advisory role in the coming months. The exact date of her departure from the COO position has not been set, as the company is currently in the process of identifying and preparing her successor.

Baird, who has had a decades-long career with Hims & Hers, will remain with the organization to ensure a smooth transition of her duties. The company plans to enter into a long-term agreement with Baird so that it can continue to benefit from her specialized expertise even after she steps down from her current role.

This development was disclosed in an 8-K filing with the Securities and Exchange Commission on Monday, April 21, 2025. The filing did not provide further details on the reasons behind Baird’s transition or the search for her replacement. It is standard practice for companies to file an 8-K to inform the public and shareholders about significant changes within the company, including the departure of key executives.

Hims & Hers, previously known as Oaktree Acquisition Corp ., is incorporated in Delaware and headquartered in San Francisco. The company has been at the forefront of the telehealth industry, offering a variety of health and wellness solutions directly to consumers.

Investors and stakeholders will be watching closely as the company navigates this transition in leadership. With its current market capitalization of $5.7 billion and trading near its InvestingPro Fair Value, the company appears well-positioned for its next phase of growth. The announcement is based on a press release statement and reflects the facts presented without speculation on the potential impact of Baird’s role change. Discover 13 additional exclusive insights and detailed financial analysis available through the comprehensive Pro Research Report.

In other recent news, Hims & Hers Health, Inc. reported promising first-quarter online revenue projections, expected to range between $567 million and $601 million, exceeding the Visible Alpha consensus of $528.4 million. Despite this positive outlook, BofA Securities maintained an Underperform rating for the company with a price target of $22, citing a slowdown in year-over-year sales growth to 78% in March. Jefferies adjusted its price target for Hims & Hers to $25, maintaining a Hold rating, noting the company’s strategic shift to marketing branded GLP-1 medications like tirzepatide and semaglutide. Truist Securities kept a Hold rating with a $39 target, highlighting the company’s expansion into weight-loss treatments, including generic liraglutide and branded tirzepatide. Meanwhile, Leerink Partners retained a Market Perform rating with a $40 target, emphasizing the addition of Eli Lilly (NYSE:LLY)’s Zepbound and generic liraglutide to Hims & Hers’ weight loss product lineup. Analysts express concerns over the high costs of branded offerings and potential regulatory scrutiny of combination medications. The company’s strategy to enhance its product offerings and competitive pricing is expected to impact margins, with some analysts cautious about the ambitious growth targets for the second half of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.